ETFIQData as of Nov 18, 2026. · etfiq.com/funds/rfg

RFG Fact Sheet: Invesco S&P MidCap 400 Pure Growth ETF

Share
$53.84
close, Nov 18, 2026

Over the year to Nov 18, 2026, RFG returned +6.9% in total and charged 0.35% a year.

1-year total return
+6.9%
to Nov 18, 2026
Expense ratio
0.35%
a year
Net assets
$297m
on Nov 17, 2026
Net flow, last 5 trading days
$0
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

RFG $10,686 +6.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month−6.6%
3 months−14.0%
Year to date+2.7%
1 year+6.9%
3 years+39.5%
5 years+14.1%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Halozyme Therapeutics Inc2.79%
Medpace Holdings Inc2.34%
TechnipFMC PLC2.20%
Five Below Inc2.02%
Exelixis Inc2.01%
Valaris Ltd1.90%
ATI Inc1.84%
Woodward Inc1.81%
InterDigital Inc1.78%
United Therapeutics Corp1.71%

RFG top ten by weight, 20.4% of the fund, of its 101 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the S&P MidCap 400 Pure Growth Index · First traded Mar 7, 2006 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, RFG Fact Sheet: Invesco S&P MidCap 400 Pure Growth ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/rfg/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/rfg.